Meta-iodobenzylguanidine in neuroblastoma: From diagnosis to therapy

Nuclear Medicine Communications

Volumn 23, Issue 1, 2002, Pages 3-4

  Mitjavila, M ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; (3 IODOBENZYL)GUANIDINE I 131; CISPLATIN;

BRAIN TUMOR; EDITORIAL; HUMAN; NEUROBLASTOMA; CANCER SCINTISCANNING; CANCER STAGING; DIAGNOSTIC IMAGING; RADIOISOTOPE THERAPY; TREATMENT PLANNING;

3-IODOBENZYLGUANIDINE; BRAIN NEOPLASMS; HUMAN; IODINE RADIOISOTOPES; NEUROBLASTOMA; RADIOPHARMACEUTICALS;

EID: 0036134328     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200201000-00002     Document Type: Editorial

References (16)

1. 131I-MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983; 24: 672-682.
2. Smets LA, Janssen M, Rutgers M et al. Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodobenzylguanidine in SK-N-SH neuroblastoma and PC12 pheochromocytoma cells. Int J Cancer 1991; 48: 609-615.
3. Brodeur GM, Pritchard J, Berthold F et al. Revision of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477.
4. Shulkin B, Shapiro R, Hutchinson. Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma. J Nucl Med 1992; 33: 1735-1740.
5. Perel Y, Conway J, Kletzel M et al. Clinical impact and prognosis value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999; 21: 13-18.
6. Gordon I, Peters A, Gutman A et al. Skeletal assessment in neuroblastoma - the pitfalls of iodine-123-MIBG scans. J Nucl Med 1990; 31: 129-134.
7. Gilday D, Greenberg M. Editorial: The controversy about the nuclear medicine investigation of neuroblastoma. J Nucl Med 1990; 31: 135.
8. 131I-metaiodobenzylguanidine in the treatment of neural crest tumors. J Nucl Biol Med 1991; 35: 177-362.
9. Lashford LS, Lewis IJ, Fielding SL et al. Phase I/II study of iodine-131-metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom children’s cancer study group investigation. J Clin Oncol 1992; 10: 1889-1896.
10. 131I-MIBG therapy in neuroblastoma: mechanism, rationale, and current status. Med Pediatr Oncol 1999; 32: 427-431.
11. 131I-metaiodobenzylguanidine, high dose melphalan and total body irradation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer 1995; 31A: 252-256.
12. 131I-MIBG as a first line treatment in advanced neuroblastoma. Q J Nucl Med 1995; 39(Suppl. 1): 61-64.
13. 131I-meta-iodobenzylguanidine (MIBG) and cisplatin. Eur J Nucl Med 1995; 31A: 606-611.
14. 131I-MIBG and multiple drug chemotherapy. Br J Cancer 2001; 84: 460-464.
15. 123I-MIBG whole body scan scoring method application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995; 31A: 256-261.
16. Frappaz D, Bonneu A, Chauvot P et al. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group. Med Pediatr Oncol 2000; 34: 237-241.